Updated:
Zealand Pharma A/S
Zealand Pharma was founded in 1998 by a team of Danish scientists specializing in peptide therapeutics, a drug class that mimics naturally occurring...
Zealand Pharma A/S
Zealand Pharma was founded in 1998 by a team of Danish scientists specializing in peptide therapeutics, a drug class that mimics naturally occurring proteins. The company has remained headquartered in Copenhagen, with Emmanuel Dulac taking the CEO role in 2023, steering a pipeline focused on metabolic disorders including obesity, diabetes, and liver disease. The firm's strategy centers on developing peptide-based drugs internally and through partnerships. Three products have reached market: dasiglucagon (for hypoglycemia), Zegalogue (dasiglucagon injection for severe hypoglycemia, approved in the US), and the glucagon/GLP-1 dual agonist being co-developed with Boehringer Ingelheim. Additional pipeline candidates target obesity and NASH. Zealand partners with larger pharma — co-investment and royalty structures with Boehringer Ingelheim and others — rather than building its own commercial sales force globally. Zealand employs roughly 200 people, mainly in R&D and clinical operations out of Copenhagen. The firm maintains a US subsidiary in Lexington, Massachusetts, handling regulatory and commercial activities for the US market. In May 2025, Zealand announced positive Phase 2b data for its GLP-1/glucagon dual agonist survodutide in obesity, boosting the stock 30 percent (per Reuters, May 2025). The company does not operate a dedicated investment arm or philanthropic foundation; its capital allocation focuses on clinical development and licensing. Zealand's structural differentiator is its dual-listed ADR structure on Nasdaq US, which provides a liquidity channel for US investors while keeping the primary listing and regulatory oversight in Denmark. This hybrid model — European biotech with direct US market access — is rare among small-cap European drug developers and allows US-based allocators to hold the equity without cross-border frictions."
General information
Firm type
Asset Manager
Year founded
1998
AUM
Undisclosed
Location
Region
Europe
Country
Denmark
City
Copenhagen
Corporate office
Copenhagen, Denmark
Principals
Emmanuel Dulac
President & CEO
Henrik Kruse Petersen
Chief Financial Officer
Adam Steensberg
Executive Vice President & Chief Medical Officer
Sector focus
Frequently asked questions
Who runs investment decisions at Zealand Pharma?
Emmanuel Dulac, President & CEO, sets overall strategy. The R&D and partnership decisions are led by Adam Steensberg, EVP & Chief Medical Officer. Capital allocation is handled by the executive team with board oversight. The firm does not have a separate investment committee beyond its full board.
How does Zealand Pharma generate revenue?
Zealand generates revenue through product sales of approved drugs — currently Zegalogue (dasiglucagon) — and through licensing, milestone payments, and royalties from partnerships. Its largest partnership is with Boehringer Ingelheim for survodutide (obesity/NASH). The firm does not operate a direct sales force for all geographies; it relies on partners for commercial execution outside Scandinavia.
Is Zealand Pharma a family office or an asset manager?
Zealand Pharma is a publicly traded biopharmaceutical company, not a family office or asset manager. It develops drugs and is owned by public shareholders. The firm has no investment arm or single-family-office structure. Its ADR listing on Nasdaq US makes it accessible to US allocators as a direct equity holding.
What investment stages does Zealand Pharma target?
Zealand does not make investments — it is a drug development company. It partners with larger pharmaceutical firms for late-stage development and commercialization. The firm's own R&D spending targets preclinical through Phase 2b clinical trials, with later-stage costs shared via co-development agreements.
Which sectors does Zealand Pharma explicitly avoid?
Zealand focuses exclusively on peptide-based therapeutics for metabolic diseases. It does not pursue oncology, rare diseases, gene therapy, or vaccines. The firm's stated strategy is to remain centered on obesity, diabetes, and liver disease.
How is Zealand Pharma related to the Danish biotech ecosystem?
Zealand is a core player in the Danish biotech cluster anchored by Novo Nordisk. The firm was founded by scientists from the University of Copenhagen and has retained deep ties to that ecosystem. Several Zealand alumni have founded or joined other Danish biotechs. The cluster provides talent, laboratory facilities, and investor access.
Does Zealand Pharma maintain philanthropic structures or a foundation?
Zealand Pharma does not operate a philanthropic foundation or a separate charitable entity. The firm has no public record of a corporate foundation. Its social impact is limited to its drug development pipeline, which targets serious metabolic diseases. The company's listing structure includes no sliding-scale dividend or charitable commitment.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: